Proceedings of the International scientific and practical conference ― Cambridge Science and Education Conference‖ (February 23-25, 2026) / Publisher website: www.naukainfo.com. – Cambridge, United Kingdom, 2026. - 289 p.

79 Engl J Med. 2018;379(15):1416–30. 3. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchuk ova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a ran domised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208. 4. Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Cal lum J, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97:1591–600. 5. Gupta V, Kennedy JA, Capo-Chichi JM, Kim S, Hu ZH, Alyea EP, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4(21):5562– 73. 6. Álvaro Jara-Gutiérrez and Victoriano Baladrón. The Role of Prostaglandins in Different Types of Cancer. Cells 2021, 10, 1487. URL: https://doi.org/10.3390/cells10061487 7. Calder, P.C. Eicosanoids. Essays Biochem. 2020, 64, 423–441.URL: https://doi.org/10.1042/EBC20190083 8. Kushwaha V., Agrawal P., Vekaria H., Das A., et al. Prostaglandins: an overview. European Journal of Pharmaceutical and Medical Research, 2024, 11(1), 130-139 9. Yin Yuan and Steven W. Lane. Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series. Haematologica | 110 April 2025 Р. 825-827